A
551.22
-26.67 (-4.62%)
| Previous Close | 577.89 |
| Open | 573.28 |
| Volume | 425,164 |
| Avg. Volume (3M) | 399,290 |
| Market Cap | 35,542,499,328 |
| Price / Earnings (TTM) | 33.55 |
| Price / Earnings (Forward) | 59.17 |
| Price / Sales | 14.96 |
| Price / Book | 6.42 |
| 52 Weeks Range | |
| Earnings Date | 31 Jul 2025 |
| Profit Margin | 40.26% |
| Operating Margin (TTM) | 17.50% |
| Diluted EPS (TTM) | 16.41 |
| Quarterly Revenue Growth (YOY) | 95.70% |
| Total Debt/Equity (MRQ) | 0.71% |
| Current Ratio (MRQ) | 7.29 |
| Operating Cash Flow (TTM) | -82.75 M |
| Levered Free Cash Flow (TTM) | -143.39 M |
| Return on Assets (TTM) | -0.21% |
| Return on Equity (TTM) | 17.36% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | argenx SE | Bullish | Bullish |
AIStockmoo Score
1.4
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 1.38 |
|
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Institutions | 55.51% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 1,065.00 (Guggenheim, 93.21%) | Buy |
| Median | 717.50 (30.17%) | |
| Low | 680.00 (Baird, 23.36%) | Buy |
| Average | 781.83 (41.84%) | |
| Total | 6 Buy | |
| Avg. Price @ Call | 556.89 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 11 Jun 2025 | 720.00 (30.62%) | Buy | 574.96 |
| 10 Jun 2025 | 720.00 (30.62%) | Buy | 575.46 | |
| Wedbush | 11 Jun 2025 | 715.00 (29.71%) | Buy | 574.96 |
| 16 Apr 2025 | 715.00 (29.71%) | Buy | 587.59 | |
| Baird | 13 May 2025 | 680.00 (23.36%) | Buy | 542.47 |
| Citigroup | 09 May 2025 | 803.00 (45.68%) | Buy | 549.65 |
| 17 Apr 2025 | 796.00 (44.41%) | Buy | 596.20 | |
| Guggenheim | 09 May 2025 | 1,065.00 (93.21%) | Buy | 549.65 |
| Oppenheimer | 09 May 2025 | 708.00 (28.44%) | Buy | 549.65 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |